Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of AGN-151607 to prevent post-operative atrial fibrillation after open-chest cardiac surgery
2017-004399-68Phase 2Unknown
- Sponsor
- Allergan
- Start
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in Atrial fibrillation (AFib) (2 arms), sponsored by Allergan. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2017-004399-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004399-68.